• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Exploration and practice: New integration of cellular therapy and hematopoietic stem cell transplantation.

作者信息

Huang Ruihao, Zhang Xi

机构信息

Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China.

Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China.

出版信息

Chin Med J (Engl). 2025 Jun 5;138(11):1261-1265. doi: 10.1097/CM9.0000000000003558. Epub 2025 May 19.

DOI:10.1097/CM9.0000000000003558
PMID:40387529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12151027/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22a8/12151027/2f904a628ebf/cm9-138-1261-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22a8/12151027/2f904a628ebf/cm9-138-1261-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22a8/12151027/2f904a628ebf/cm9-138-1261-g001.jpg

相似文献

1
Exploration and practice: New integration of cellular therapy and hematopoietic stem cell transplantation.探索与实践：细胞治疗与造血干细胞移植的新整合
Chin Med J (Engl). 2025 Jun 5;138(11):1261-1265. doi: 10.1097/CM9.0000000000003558. Epub 2025 May 19.
2
[Exploration and practice of novel models of cellular therapy and hematopoietic stem cell transplantation].[细胞治疗与造血干细胞移植新型模式的探索与实践]
Zhonghua Xue Ye Xue Za Zhi. 2024 Feb 14;45(2):105-108. doi: 10.3760/cma.j.cn121090-20230928-00150.
3
[Modalities of mobilization and hematopoietic stem cells objectives in autologous transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].[自体移植中动员方式及造血干细胞目标：法语国家骨髓移植与细胞治疗协会（SFGM-TC）指南]
Bull Cancer. 2020 Jan;107(1S):S44-S51. doi: 10.1016/j.bulcan.2019.08.007. Epub 2019 Sep 27.
4
Recognition of Hematopoietic Stem Cell Transplantation and Cellular Therapy Expertise to Promote Care Accessibility: A Formally Credentialed Area of Focused Competence in Canada.识别造血干细胞移植和细胞治疗专业知识，以促进护理的可及性：加拿大正式认证的重点关注领域的能力。
Transplant Cell Ther. 2021 Sep;27(9):702-706. doi: 10.1016/j.jtct.2021.06.013. Epub 2021 Jun 19.
5
Nursing Experience in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia.异基因造血干细胞移植治疗急性淋巴细胞白血病的护理体会。
Altern Ther Health Med. 2024 Sep;30(9):359-365.
6
Chimerism of bone marrow mesenchymal stem/stromal cells in allogeneic hematopoietic cell transplantation: is it clinically relevant?异基因造血细胞移植中骨髓间充质干/基质细胞的嵌合现象：其具有临床相关性吗？
Chimerism. 2013 Jul-Sep;4(3):78-83. doi: 10.4161/chim.25609. Epub 2013 Jul 11.
7
Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.异基因造血干细胞移植患者使用来特莫韦的真实世界安全性和有效性：日本上市后监测的最终结果。
Clin Drug Investig. 2024 Jul;44(7):527-540. doi: 10.1007/s40261-024-01376-w. Epub 2024 Jun 27.
8
[Crohn's disease and autologous hemapoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].[克罗恩病与自体造血细胞移植：法语国家骨髓移植与细胞治疗协会（SFGM-TC）指南]
Bull Cancer. 2020 Dec;107(12S):S140-S150. doi: 10.1016/j.bulcan.2020.08.009. Epub 2020 Oct 14.
9
American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States.美国移植与细胞治疗学会药房特别兴趣小组关于美国造血细胞移植和细胞治疗患者 COVID-19 的药房实践管理和临床管理的立场声明。
Biol Blood Marrow Transplant. 2020 Jun;26(6):1043-1049. doi: 10.1016/j.bbmt.2020.04.005. Epub 2020 Apr 17.
10
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines.接受造血细胞移植或嵌合抗原受体T细胞疗法的老年人的美国老年评估实践：来自移植与细胞治疗学会衰老特别兴趣小组和实践指南委员会的一项医师调查。
Transplant Cell Ther. 2025 May;31(5):285-296. doi: 10.1016/j.jtct.2025.02.014. Epub 2025 Feb 15.

本文引用的文献

1
Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update.中国异基因造血干细胞移植后白血病复发监测、治疗与预防的专家共识：2024 年更新版。
Cancer Lett. 2024 Nov 28;605:217264. doi: 10.1016/j.canlet.2024.217264. Epub 2024 Sep 25.
2
Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination.免疫原性细胞死亡在癌症免疫治疗中的新作用：通过联合应用推进下一代 CAR-T 细胞免疫治疗。
Cancer Lett. 2024 Aug 28;598:217079. doi: 10.1016/j.canlet.2024.217079. Epub 2024 Jun 25.
3
Human amniotic epithelial stem cell is a cell therapy candidate for preventing acute graft-versus-host disease.
人羊膜上皮干细胞是预防急性移植物抗宿主病的细胞治疗候选物。
Acta Pharmacol Sin. 2024 Nov;45(11):2339-2353. doi: 10.1038/s41401-024-01283-y. Epub 2024 May 27.
4
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.序贯 CD7 CAR T 细胞治疗与异基因造血干细胞移植而不进行移植物抗宿主病预防。
N Engl J Med. 2024 Apr 25;390(16):1467-1480. doi: 10.1056/NEJMoa2313812.
5
Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.嵌合抗原受体 T 细胞与高剂量化疗/自体造血干细胞移植联合治疗复发/难治性大 B 细胞淋巴瘤显示出令人瞩目的临床疗效，并改善了嵌合抗原受体 T 细胞的行为。
J Immunother Cancer. 2024 Apr 16;12(4):e008857. doi: 10.1136/jitc-2024-008857.
6
ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft--host disease in adults.ERS/EBMT 临床实践指南：成人肺慢性移植物抗宿主病的治疗。
Eur Respir J. 2024 Mar 28;63(3). doi: 10.1183/13993003.01727-2023. Print 2024 Mar.
7
Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.间充质基质细胞加巴利昔单抗作为二线治疗改善激素难治性急性移植物抗宿主病的反应：一项多中心、随机、对照试验。
BMC Med. 2024 Feb 27;22(1):85. doi: 10.1186/s12916-024-03275-5.
8
Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial.异体造血干细胞移植后预防慢性移植物抗宿主病的间充质干细胞：一项开放标签随机临床试验。
JAMA Oncol. 2024 Feb 1;10(2):220-226. doi: 10.1001/jamaoncol.2023.5757.
9
In vivo hematopoietic stem cell modification by mRNA delivery.mRNA 递送介导的体内造血干细胞修饰。
Science. 2023 Jul 28;381(6656):436-443. doi: 10.1126/science.ade6967. Epub 2023 Jul 27.
10
Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后复发急性白血病患者的预后因素和临床结局。
Bone Marrow Transplant. 2023 Aug;58(8):863-873. doi: 10.1038/s41409-023-01989-3. Epub 2023 Apr 29.